Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2014

01-02-2014 | Research Article

Survivin rs9904341 (G>C) polymorphism contributes to cancer risk: an updated meta-analysis of 26 studies

Authors: Lei Xu, Xin Zhou, Lin Xu, Rong Yin

Published in: Tumor Biology | Issue 2/2014

Login to get access

Abstract

Survivin, a member of the inhibitor of apoptosis protein family, encoded by BIRC5, is involved in the regulation of apoptosis and in cell cycle control. Emerging evidences indicate that polymorphism in BIRC5 promoter (rs9904341) is associated with cancer risk, but the results of individually published studies are inconclusive. Thus, an updated meta-analysis was performed. PubMed was searched for all eligible studies. Pooled odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated to assess the association strength. Stratified analysis was performed by cancer type, source of control, genotyping method, and ethnicity. A number of 26 studies, including 6,041 cases and 7,567 controls were analyzed in this meta-analysis. Overall, significantly increased cancer risk was associated with survivin rs9904341 polymorphism when all studies were pooled (CC vs. GG: OR = 1.36, 95 % CI = 1.09–1.69; P heterogeneity < 0.001; CC vs GC/GG: OR = 1.32, 95 % CI = 1.11–1.57; P heterogeneity < 0.001). Stratified analysis by cancer type revealed that the survivin rs9904341 polymorphism may increase the risk of colorectal cancer, renal cell cancer, gastric cancer, and bladder cancer. Further subgroup analysis by ethnicity indicated that there was a statistically increased cancer risk in Asians but not Caucasians. In this updated meta-analysis of 26 studies, we conclude that the survivin rs9904341 polymorphism might contribute to risk of various cancers, especially in Asian populations.
Literature
1.
2.
Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer. 2004;4(11):850–60.PubMedCrossRef
3.
Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996;273(5281):1516–7.PubMedCrossRef
4.
Mondello C, Scovassi AI. Apoptosis: a way to maintain healthy individuals. Genome stability and human diseases. New York: Springer; 2010. p. 307–23.CrossRef
5.
6.
Ma S, Shen L, Qian N, Chen K. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited. Cancer Biomark. 2011;10(3–4):155–62.PubMed
7.
Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411(6835):342–8.PubMedCrossRef
8.
Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267(5203):1456–62.PubMedCrossRef
9.
Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22(53):8581–9.PubMedCrossRef
10.
Wang L, Shao ZM. Cyclin E expression and prognosis in breast cancer patients: a meta-analysis of published studies. Cancer Invest. 2006;24(6):581–7.PubMedCrossRef
11.
Xu Y, Fang F, Ludewig G, Jones G, Jones D. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol. 2004;23(9):527–37.PubMedCrossRef
12.
Lu D, Qian J, Yin X, Xiao Q, Wang C, Zeng Y. Expression of PTEN and survivin in cervical cancer: promising biological markers for early diagnosis and prognostic evaluation. Br J Biomed Sci. 2012;69(4):143–6.PubMed
13.
Li XB, Li SN, Yang ZH, Cao L, Duan FL, Sun XW. Polymorphisms of survivin and its protein expression are associated with colorectal cancer susceptibility in Chinese population. DNA Cell Biol. 2013;32(5):236–42.PubMedCrossRef
14.
Fawzy A, Gaafar R, Kasem F, Ali SS, Elshafei M, Eldeib M. Importance of serum levels of angiopoietin-2 and survivin biomarkers in non-small cell lung cancer. J Egypt Natl Cancer Inst. 2012;24(1):41–5.CrossRef
15.
Sun YW, Xuan Q, Shu QA, Wu SS, Chen H, Xiao J, et al. Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma. Genet Mol Res. 2013;12(2):1045–53.PubMedCrossRef
16.
Rosato A, Menin C, Boldrin D, Santa SD, Bonaldi L, Scaini MC, et al. Survivin expression impacts prognostically on NSCLC but not SCLC. Lung Cancer. 2013;79(2):180–6.PubMedCrossRef
17.
Wu SF, Zhang JW, Qian WY, Yang YB, Liu Y, Dong Y, et al. Altered expression of survivin, Fas and FasL contributed to cervical cancer development and metastasis. Eur Rev Med Pharmacol Sci. 2012;16(15):2044–50.PubMed
18.
Zhang LQ, Wang J, Jiang F, Xu L, Liu FY, Yin R. Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. PLoS One. 2012;7(3):e34100.PubMedCentralPubMedCrossRef
19.
Radojevic-Skodric S, Basta-Jovanovic G, Brasanac D, Nikolic N, Bogdanovic L, Milicic B, et al. Survivin gene promoter −31 G/C polymorphism is associated with Wilms' tumor susceptibility in Serbian children. J Pediatr Hematol Oncol. 2012;34(8):e310–4.PubMedCrossRef
20.
Liarmakopoulos E, Theodoropoulos G, Vaiopoulou A, Rizos S, Aravantinos G, Kouraklis G, et al. Effects of stromal cell-derived factor-1 and survivin gene polymorphisms on gastric cancer risk. Mol Med Rep. 2013;7(3):887–92.PubMed
21.
Aynaci E, Coskunpinar E, Eren A, Kum O, Oltulu YM, Akkaya N et al. Association between survivin gene promoter −31G/C and −644C/T polymorphisms and non-small cell lung cancer. Genet Mol Res. 2013. doi:10.​4238/​2013.
22.
Marques I, Teixeira AL, Ferreira M, Assis J, Lobo F, Mauricio J, et al. Influence of survivin (BIRC5) and caspase-9 (CASP9) functional polymorphisms in renal cell carcinoma development: a study in a southern European population. Mol Biol Rep. 2013;40(8):4819–26.PubMedCrossRef
23.
Weng CJ, Hsieh YH, Chen MK, Tsai CM, Lin CW, Yang SF. Survivin SNP–carcinogen interactions in oral cancer. J Dent Res. 2012;91(4):358–63.PubMedCrossRef
24.
Qin C, Cao Q, Li P, Ju X, Wang M, Chen J, et al. Functional promoter −31G>C variant in survivin gene is associated with risk and progression of renal cell cancer in a Chinese population. PLoS One. 2012;7(1):e28829.PubMedCentralPubMedCrossRef
25.
Yazdani N, Sayahpour FA, Haghpanah V, Amiri P, Shahrabi-Farahani M, Moradi M, et al. Survivin gene polymorphism association with papillary thyroid carcinoma. Pathol Res Pract. 2012;208(2):100–3.PubMedCrossRef
26.
Li Y, Wang J, Jiang F, Lin W, Meng W. Association of polymorphisms in survivin gene with the risk of hepatocellular carcinoma in Chinese Han population: a case control study. BMC Med Genet. 2012;13:1.PubMedCentralPubMedCrossRef
27.
Jaiswal PK, Goel A, Mandhani A, Mittal RD. Functional polymorphisms in promoter survivin gene and its association with susceptibility to bladder cancer in North Indian cohort. Mol Biol Rep. 2012;39(5):5615–21.PubMedCrossRef
28.
Hsieh YS, Tsai CM, Yeh CB, Yang SF, Hsieh YH, Weng CJ. Survivin T9809C, an SNP located in 3′-UTR, displays a correlation with the risk and clinicopathological development of hepatocellular carcinoma. Ann Surg Oncol. 2012;19 Suppl 3:S625–33.PubMedCrossRef
29.
Zahedi P, Aminimoghaddam S, Sayahpour FA, Haghpanah V, Amiri P, Fereidoni F, et al. Association of survivin gene polymorphism with endometrial cancer. Int J Gynecol Cancer. 2012;22(1):35–7.PubMedCrossRef
30.
Antonacopoulou AG, Floratou K, Bravou V, Kottorou A, Dimitrakopoulos FI, Marousi S, et al. The survivin −31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Cell Oncol (Dordr). 2011;34(4):381–91.PubMedCrossRef
31.
Ma F, Zhang H, Zhai Y, Huang W, Zhao C, Ou S, et al. Functional polymorphism −31C/G in the promoter of BIRC5 gene and risk of nasopharyngeal carcinoma among chinese. PLoS One. 2011;6(2):e16748.PubMedCentralPubMedCrossRef
32.
Bayram S, Akkiz H, Bekar A, Akgollu E. The association between the survivin −31G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish population. Cancer Epidemiol. 2011;35(6):555–9.PubMedCrossRef
33.
Borges Bdo N, Burbano RR, Harada ML. Survivin −31C/G polymorphism and gastric cancer risk in a Brazilian population. Clin Exp Med. 2011;11(3):189–93.PubMedCrossRef
34.
Kawata N, Tsuchiya N, Horikawa Y, Inoue T, Tsuruta H, Maita S, et al. Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility. Int J Cancer. 2011;129(8):1872–80.PubMedCrossRef
35.
Upadhyay R, Khurana R, Kumar S, Ghoshal UC, Mittal B. Role of survivin gene promoter polymorphism (−31G>C) in susceptibility and survival of esophageal cancer in northern India. Ann Surg Oncol. 2011;18(3):880–7.PubMedCrossRef
36.
Theodoropoulos GE, Michalopoulos NV, Panoussopoulos SG, Taka S, Gazouli M. Effects of caspase-9 and survivin gene polymorphisms in pancreatic cancer risk and tumor characteristics. Pancreas. 2010;39(7):976–80.PubMedCrossRef
37.
Yang X, Xiong G, Chen X, Xu X, Wang K, Fu Y, et al. Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2009;135(10):1341–9.PubMedCrossRef
38.
Wang YH, Chiou HY, Lin CT, Hsieh HY, Wu CC, Hsu CD, et al. Association between survivin gene promoter −31 C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology. 2009;73(3):670–4.PubMedCrossRef
39.
Gazouli M, Tzanakis N, Rallis G, Theodoropoulos G, Papaconstantinou I, Kostakis A, et al. Survivin −31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis. 2009;24(2):145–50.PubMedCrossRef
40.
Yang L, Zhu H, Zhou B, Gu H, Yan H, Tang N, et al. The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. Dig Dis Sci. 2009;54(5):1021–8.PubMedCrossRef
41.
Cheng ZJ, Hu LH, Huang SJ. Correlation of −31G/C polymorphisms of survivin promoter to tumorigenesis of gastric carcinoma. Ai Zheng. 2008;27(3):258–63.PubMed
42.
Jang JS, Kim KM, Kang KH, Choi JE, Lee WK, Kim CH, et al. Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer. 2008;60(1):31–9.PubMedCrossRef
43.
Borbely AA, Murvai M, Szarka K, Konya J, Gergely L, Hernadi Z, et al. Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol. 2007;60(3):303–6.PubMedCrossRef
44.
Wang X, Huang L, Xu Y, Shi Z, Wang Y, Zhang J, et al. Association between survivin −31G>C promoter polymorphism and cancer risk: a meta-analysis. Eur J Hum Genet. 2012;20(7):790–5.PubMedCrossRef
45.
Srivastava K, Srivastava A, Mittal B. Survivin promoter −31G/C (rs9904341) polymorphism and cancer susceptibility: a meta-analysis. Mol Biol Rep. 2012;39(2):1509–16.PubMedCrossRef
46.
Guo SW, Thompson EA. Performing the exact test of Hardy–Weinberg proportion for multiple alleles. Biometrics. 1992;48(2):361–72.PubMedCrossRef
47.
Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820–6.PubMedCrossRef
48.
49.
Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med. 1991;10(11):1665–77.PubMedCrossRef
50.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.PubMedCrossRef
51.
Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3(8):917–21.PubMedCrossRef
52.
Deveraux QL, Reed JC. IAP family proteins—suppressors of apoptosis. Genes Dev. 1999;13(3):239–52.PubMedCrossRef
53.
Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396(6711):580–4.PubMedCrossRef
54.
Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med. 2001;7(12):542–7.PubMedCrossRef
55.
Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006;5(5):1087–98.PubMedCrossRef
56.
Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002;277(5):3247–57.PubMedCrossRef
57.
Mityaev MV, Kopantzev EP, Buzdin AA, Vinogradova TV, Sverdlov ED. Functional significance of a putative sp1 transcription factor binding site in the survivin gene promoter. Biochemistry (Mosc). 2008;73(11):1183–91.CrossRef
58.
Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med. 2002;4(2):45–61.PubMedCrossRef
59.
Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96(6):434–42.PubMedCrossRef
Metadata
Title
Survivin rs9904341 (G>C) polymorphism contributes to cancer risk: an updated meta-analysis of 26 studies
Authors
Lei Xu
Xin Zhou
Lin Xu
Rong Yin
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1229-6

Other articles of this Issue 2/2014

Tumor Biology 2/2014 Go to the issue

Research Article

Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS

Research Article

CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion

Research Article

Quantitative assessment of the association between XPC Lys939Gln polymorphism and cutaneous melanoma risk

Research Article

Prognostic factors of carcinoma of the ampulla of Vater after surgery

Research Article

Gelatinase B (−1562C/T) polymorphism in tumor progression and invasion of breast cancer

Research Article

Aberrant TIG1 methylation associated with its decreased expression and clinicopathological significance in hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits